Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06706973

Acronym

AIRC-Chiocca

Enrollment

Registered

2024-11-27

Start date

2024-03-06

Completion date

2030-04-04

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

PROFILING AND TARGETING EPIGENETIC MARKS, HEAD AND NECK CANCER

Brief summary

Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and feasible option to build upon. Our overarching hypothesis is that unique histone marks distinguish HPV+ and HPV- HNC and that specific histone modifiers are novel mediators of HNC tumorigenesis in an HPV specific manner

Detailed description

Head and neck cancer (HNC) is a highly heterogeneous disease, involving diverse anatomical sites including oral cavity, larynx and oropharynx. HNC risk factors include tobacco smoking and alcohol consumption and, especially for the subtype of oropharyngeal cancers (OPC), human papillomavirus (HPV) infection

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

• Age: Adults aged ≥ 18 years diagnosed with HNC * Sex: Both male and female * Human papilloma virus (HPV) test: Both positive and negative. * Tumor: primary tumors, treatment naïve, squamous cell carcinoma * Cancer stage: I-IV * Anatomic location: oral cavity, larynx, oropharynx * Tumor fragments not required for diagnostics

Exclusion criteria

* Previous radiotherapy, chemotherapy or immunotherapy for HNC * Unable to provide written informed consent

Design outcomes

Primary

Measure	Time frame	Description
PROFILING AND TARGETING EPIGENETIC MARKS TO IMPROVE DIAGNOSIS AND THERAPEUTIC APPROACHES IN HEAD AND NECK CANCER	2 years	define and fully characterize histone Post-Translational Modifications (hPTMs) and differentially expressed chromatin modifiers in HPV+ vs HPV- HNC through cutting-edge methodologies

Countries

Italy

Contacts

Primary ContactSusanna Chiocca, Doctor

susanna.chiocca@ieo.it00390257488835

Backup Contactfrancesca lombardi, dr

francesca.lombardi@ieo.it0039-02-57489425

Outcome results